KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity: 2018-2024

Historic Liabilities and Shareholders Equity for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $539.4 million.

  • Adaptive Biotechnologies' Liabilities and Shareholders Equity fell 12.16% to $490.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 15.97%. This contributed to the annual value of $539.4 million for FY2024, which is 18.42% down from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' Liabilities and Shareholders Equity is $539.4 million, which was down 18.42% from $661.1 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year Liabilities and Shareholders Equity high stood at $1.1 billion for FY2020, and its period low was $539.4 million during FY2024.
  • For the 3-year period, Adaptive Biotechnologies' Liabilities and Shareholders Equity averaged around $685.7 million, with its median value being $661.1 million (2023).
  • Per our database at Business Quant, Adaptive Biotechnologies' Liabilities and Shareholders Equity grew by 22.37% in 2020 and then dropped by 22.82% in 2023.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Liabilities and Shareholders Equity stood at $1.1 billion in 2020, then declined by 17.29% to $923.3 million in 2021, then fell by 7.23% to $856.6 million in 2022, then declined by 22.82% to $661.1 million in 2023, then fell by 18.42% to $539.4 million in 2024.